Genmab A/S (GMAB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2025, filed Feb 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GMAB SEC filings page.
Genmab A/S (GMAB) reported $3.7B in revenue for fiscal year 2025, up 19.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue expanded, but 2025 profit margins retreated while cash generation held up and the balance sheet became much larger and less liquid.
Cash conversion diverged from profitability: in FY2025, net profit margin fell to25.9% while free cash flow reached$1.149B . That contrasts with FY2024, when margin was36.3% and free cash flow was$1.099B , showing cash output held up better than reported earnings.
Balance-sheet scale changed faster than debt: total assets nearly doubled to
Capital intensity remains low: free cash flow of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Genmab A/S's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Genmab A/S, and counted as zero in the overall score.
Genmab A/S's revenue surged 19.2% year-over-year to $3.7B, reflecting rapid business expansion. This strong growth earns a score of 86/100.
Genmab A/S carries a low D/E ratio of 0.02, meaning only $0.02 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.
Genmab A/S's current ratio of 2.02 indicates adequate short-term liquidity, earning a score of 59/100. The company can meet its near-term obligations, though with limited headroom.
Genmab A/S converts 30.9% of revenue into free cash flow ($1.1B). This strong cash generation earns a score of 96/100.
Not available for Genmab A/S, and counted as zero in the overall score.
Genmab A/S passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Genmab A/S generates $1.23 in operating cash flow ($1.2B OCF vs $963.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Genmab A/S held $1.7B in cash against $134.0M in long-term debt as of Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
GMAB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
GMAB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q2'256-K | Q4'2410-K | Q2'246-K | Q4'2310-K |
|---|---|---|---|---|---|
| Total Assets | $12.9B+100.7% | $6.5B | $6.4B+22.6% | N/A | $5.2B |
| Current Assets | $2.9B-26.0% | $3.9B | $3.9B-20.6% | N/A | $4.9B |
| Cash & Equivalents | $1.7B+24.3% | $1.3B+108.4% | $1.4B-37.4% | $622.0M | $2.2B |
| Inventory | $18.0M+100.0% | $13.0M | $9.0M+12.5% | N/A | $8.0M |
| Accounts Receivable | $1.1B+20.5% | $998.0M | $923.0M+25.9% | N/A | $733.0M |
| Goodwill | $355.0M0.0% | $355.0M | $355.0M | N/A | $0 |
| Total Liabilities | $7.0B+450.2% | $1.2B | $1.3B+134.3% | N/A | $545.0M |
| Current Liabilities | $1.4B+91.8% | $629.0M | $744.0M+102.2% | N/A | $368.0M |
| Non-Current Liabilities | $5.6B+950.5% | $533.0M | $533.0M+201.1% | N/A | $177.0M |
| Long-Term Debt | $134.0M+2.3% | $132.0M | $131.0M+29.7% | N/A | $101.0M |
| Total Equity | $5.8B+13.8% | $5.3B+19.3% | $5.1B+9.6% | $4.4B | $4.7B |
| Retained Earnings | $4.1B+20.8% | $3.6B | $3.4B+23.9% | N/A | $2.7B |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
GMAB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
GMAB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Genmab A/S GMAB | FY2025 | $3.7B | $963.0M | 25.9% | $22.5B | 55/100 |
| Incyte Genomics Inc INCY | FY2025 | $5.1B | $1.3B | 25.0% | $22.0B | 63/100 |
| Summit Therapeutics Inc. SMMT | FY2025 | N/A | -$1.1B | N/A | $12.4B | — |
| Royalty Pharma plc RPRX | FY2025 | $2.4B | $770.9M | 32.4% | $25.2B | 44/100 |
Where Genmab A/S Ranks
Frequently Asked Questions
What is Genmab A/S's annual revenue?
Genmab A/S (GMAB) reported $3.7B in total revenue for fiscal year 2025. This represents a 19.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Genmab A/S's revenue growing?
Genmab A/S (GMAB) revenue grew by 19.2% year-over-year, from $3.1B to $3.7B in fiscal year 2025.
Is Genmab A/S profitable?
Yes, Genmab A/S (GMAB) reported a net income of $963.0M in fiscal year 2025, with a net profit margin of 25.9%.
How much debt does Genmab A/S have?
As of fiscal year 2025, Genmab A/S (GMAB) had $1.7B in cash and equivalents against $134.0M in long-term debt.
What is Genmab A/S's net profit margin?
Genmab A/S (GMAB) had a net profit margin of 25.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Genmab A/S's return on equity (ROE)?
Genmab A/S (GMAB) has a return on equity of 16.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Genmab A/S's free cash flow?
Genmab A/S (GMAB) generated $1.1B in free cash flow during fiscal year 2025. This represents a 4.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Genmab A/S's operating cash flow?
Genmab A/S (GMAB) generated $1.2B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Genmab A/S's total assets?
Genmab A/S (GMAB) had $12.9B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Genmab A/S's capital expenditures?
Genmab A/S (GMAB) invested $37.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Genmab A/S's current ratio?
Genmab A/S (GMAB) had a current ratio of 2.02 as of fiscal year 2025, which is generally considered healthy.
What is Genmab A/S's debt-to-equity ratio?
Genmab A/S (GMAB) had a debt-to-equity ratio of 0.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Genmab A/S's return on assets (ROA)?
Genmab A/S (GMAB) had a return on assets of 7.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Genmab A/S's P/E ratio?
Genmab A/S (GMAB) trades at 23.4x earnings, its market capitalization divided by net income of $963.0M net income, FY2025. The market capitalization is $22.5B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Genmab A/S's price-to-sales ratio?
Genmab A/S (GMAB) trades at 6.0x sales, its market capitalization divided by revenue of $3.7B revenue, FY2025. The market capitalization is $22.5B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Genmab A/S's Piotroski F-Score?
Genmab A/S (GMAB) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Genmab A/S's earnings high quality?
Genmab A/S (GMAB) has an earnings quality ratio of 1.23x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Genmab A/S?
Genmab A/S (GMAB) scores 55 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.